J.M. Forbes & Co’s Genocea Biosciences, Inc. GNCA Stock Holding History

J.M. Forbes & Co’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,688	Closed	-$8K	–	104
2019 Q1	$8K	Hold	1,688	–	–	﹤0.01%	100
2018 Q4	$4K	Hold	1,688	–	–	﹤0.01%	100
2018 Q3	$11K	Buy	+1,688	New	+$8.91K	﹤0.01%	104

Other funds holding GNCA

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Alyeska Investment Group

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

J.M. Forbes & Co's GNCA Position: Q2 2019 in Review

J.M. Forbes & Co sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2019, closing a stake of 1,688 shares — an estimated $8K sold.

J.M. Forbes & Co first reported a position in GNCA in Q3 2018 and held it in 3 quarters. The position peaked at $11K in Q3 2018. 45 funds tracked by Wall St. Rank hold GNCA as of Q2 2019.

J.M. Forbes & Co reported no remaining Genocea Biosciences, Inc. position as of Q2 2019 after selling out during the quarter.
J.M. Forbes & Co sold 1,688 Genocea Biosciences, Inc. shares in Q2 2019, an estimated $8K.
J.M. Forbes & Co first reported a position in Genocea Biosciences, Inc. in Q3 2018 and held it in 3 quarters.
J.M. Forbes & Co's Genocea Biosciences, Inc. position peaked at $11K in Q3 2018.
45 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2019.

Based on J.M. Forbes & Co's 13F filing for Q2 2019, filed 2 Aug 2019.